MEDFORD, Mass.--ArQule, a drug discovery chemistry company here, will collaborate with Seattle biopharmaceutical Immunex to discover and develop products for the treatment of inflammatory disorders. Immunex will gain access to ArQule's mapping array program, comprised of libraries of novel, diverse, small organic, pure compounds used for screening against biological targets in new product discovery. Immunex will use the program to identify small molecule therapeutics based on a chemokine gene discovered by the Seattle company.